^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NCAPG overexpression

    i
    Other names: NCAPG, Non-SMC Condensin I Complex Subunit G, Chromosome Condensation Protein G, Chromosome-Associated Protein G, Condensin Complex Subunit 3, Melanoma Antigen NY-MEL-3, Condensin Subunit CAP-G, XCAP-G Homolog, CAPG, Non-SMC Condensin I Complex, Subunit G, NY-MEL-3, NYMEL3, HCAP-G, CHCG, YCG1
    Entrez ID:
    64151
    over2years
    NCAPG stimulates lung adenocarcinoma cell stemness through aerobic glycolysis. (PubMed, Clin Respir J)
    NCAPG stimulated LUAD cell stemness through activation of glycolysis pathway. NCAPG may be possible biomarker for diagnosis and target for treatment of LUAD.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • POU5F1 (POU Class 5 Homeobox 1) • NCAPG (Non-SMC Condensin I Complex Subunit G) • CAPG (Capping Actin Protein, Gelsolin Like) • PKM (Pyruvate Kinase M1/2)
    |
    NCAPG overexpression
    almost3years
    The diagnostic and therapeutic value of NCAPG as a proposed biomarker candidate in acute liver failure. (PubMed, Comb Chem High Throughput Screen)
    Our study suggests that NCAPG is a preliminary tool for the diagnosis of ALF. It can affect ALF via the PI3K/AKT pathway and is a potential therapeutic target to improve prognosis.
    Journal
    |
    NCAPG (Non-SMC Condensin I Complex Subunit G) • CAPG (Capping Actin Protein, Gelsolin Like)
    |
    NCAPG overexpression
    almost4years
    NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression. (PubMed, Mol Cancer)
    This study indicates that NCAPG is one of the essential factors for NSCLC oncogenesis and progression, providing a new target for prognosis prediction and treatment of NSCLC.
    Journal
    |
    LGALS1 (Galectin 1) • NCAPG (Non-SMC Condensin I Complex Subunit G) • CAPG (Capping Actin Protein, Gelsolin Like)
    |
    NCAPG overexpression
    almost4years
    NCAPG facilitates colorectal cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition by activating the Wnt/β-catenin signaling pathway. (PubMed, Cancer Cell Int)
    NCAPG acts as an oncogene involved in the development and progression of CRC by binding to β-catenin to activate the Wnt/β-catenin signaling pathway.
    Journal
    |
    NCAPG (Non-SMC Condensin I Complex Subunit G) • CAPG (Capping Actin Protein, Gelsolin Like)
    |
    NCAPG overexpression
    4years
    NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma. (PubMed, Eur Rev Med Pharmacol Sci)
    NCAPG upregulation is associated with poor prognosis in hepatocellular carcinoma patients with vascular invasion.
    Journal
    |
    NCAPG (Non-SMC Condensin I Complex Subunit G)
    |
    NCAPG overexpression
    over4years
    NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway. (PubMed, Cancer Cell Int)
    NCAPG may promote proliferation and migration via the TGF-β signaling pathway in LUAD.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • NCAPG (Non-SMC Condensin I Complex Subunit G) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3)
    |
    NCAPG overexpression
    over5years
    Overexpression of NCAPG inhibits cardia adenocarcinoma apoptosis and promotes epithelial-mesenchymal transition through the Wnt / β-catenin signaling pathway. (PubMed, Gene)
    NCAPG overexpression can promote EMT and suppress tumor cell apoptosis via the activation of Wnt/β-catenin signaling.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • NCAPG (Non-SMC Condensin I Complex Subunit G)
    |
    BAX expression • VIM expression • NCAPG overexpression
    over5years
    Aberrant Expression of NCAPG is Associated with Prognosis and Progression of Gastric Cancer. (PubMed, Cancer Manag Res)
    Finally, Western blotting showed that NCPAG knockdown dysregulated cell cycle- and epithelial-mesenchymal transition-related molecules. Overall, the results reveal that NCAPG overexpression is a candidate prognostic biomarker and potential therapeutic target in GC.
    Journal
    |
    NCAPG (Non-SMC Condensin I Complex Subunit G)
    |
    NCAPG overexpression